Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting: 52-Week Data From the Phase 4 ARTISTYK Study. J of Skin. 2025;9(6):s649. doi:10.25251/7j9e8h28